89bio shares are trading lower after RBC Capital maintained an Outperform rating on the stock but lowered its price target from $34 to $27.
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained an Outperform rating on 89bio but lowered its price target from $34 to $27, causing the shares to trade lower.
October 11, 2023 | 4:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
89bio's stock price is trading lower due to RBC Capital's decision to lower its price target from $34 to $27, despite maintaining an Outperform rating.
RBC Capital's decision to lower its price target on 89bio from $34 to $27, despite maintaining an Outperform rating, has led to a decrease in the stock's trading price. This indicates that the market has reacted negatively to the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100